Literature DB >> 17008926

Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.

Francis K L Chan1.   

Abstract

Ulcer complications associated with the use of NSAIDs, in high-risk patients, are often caused by a failure to identify patients' risk factors, concomitant use of aspirin or multiple NSAIDs, and underutilization of gastroprotective agents. Current data suggest that cyclo-oxygenase 2 (COX2) inhibitors and some nonselective NSAIDs increase the risk of myocardial infarction. Physicians must, therefore, take into account both the gastrointestinal and the cardiovascular risks of individual patients when prescribing NSAIDs. In patients with a low cardiovascular risk, NSAIDs can be prescribed according to the level of gastrointestinal risk. Patients with a moderate gastrointestinal risk (one or two risk factors) should receive a COX2 inhibitor or an NSAID plus a PPI or misoprostol. Patients with more than two gastrointestinal risk factors or prior ulcer complications require the combination of a COX2 inhibitor and a PPI. Patients with a high cardiovascular risk (e.g. coronary heart disease or an estimated 10-year cardiovascular risk greater than 10%) should receive prophylactic aspirin and combination therapy with a PPI or misoprostol irrespective of the presence of gastrointestinal risk factors. Naproxen is the preferred NSAID because it is not associated with excess cardiovascular risk. Patients with a high cardiovascular risk and a very high gastrointestinal risk should avoid using NSAIDs or COX2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008926     DOI: 10.1038/ncpgasthep0610

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  19 in total

1.  Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial.

Authors:  Jay L Goldstein; James Aisenberg; Salam F Zakko; Manuela F Berger; William E Dodge
Journal:  Dig Dis Sci       Date:  2007-08-04       Impact factor: 3.199

Review 2.  A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain.

Authors:  Bao Yanju; Liping Yang; Baojin Hua; Wei Hou; Zhan Shi; Weidong Li; Conghuang Li; Cihui Chen; Rui Liu; Yinggang Qin; Wenliang Lv
Journal:  Support Care Cancer       Date:  2013-11-26       Impact factor: 3.603

3.  Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients.

Authors:  Soumana C Nasser; Jeanette G Nassif; Hani I Dimassi
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 4.  [Osteoarthritis: what internists should know].

Authors:  L Wildi
Journal:  Internist (Berl)       Date:  2015-05       Impact factor: 0.743

Review 5.  Evolution of topical NSAIDs in the guidelines for treatment of osteoarthritis in elderly patients.

Authors:  Paul M Arnstein
Journal:  Drugs Aging       Date:  2012-07-01       Impact factor: 3.923

6.  Synthesis of tert-butyl (substituted benzamido)phenylcarbamate derivatives: anti-inflammatory activity and docking studies.

Authors:  Shankar Bhookya; Jalapathi Pochampally; Anil Valeru; Vianala Sunitha; Saikrishna Balabadra; Vijjulatha Manga; Karunakar Rao Kudle
Journal:  J Chem Biol       Date:  2017-04-05

7.  Nononcogenic restoration of the intestinal barrier by E. coli-delivered human EGF.

Authors:  Mira Yu; Juil Kim; Jung Hoon Ahn; Yuseok Moon
Journal:  JCI Insight       Date:  2019-08-22

8.  Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs.

Authors:  Abdulwahed Al-Saeed
Journal:  Oman Med J       Date:  2011-11

Review 9.  Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety.

Authors:  Sanford H Roth
Journal:  Clin Interv Aging       Date:  2011-05-30       Impact factor: 4.458

10.  Gallic Acid Enriched Fraction of Phyllanthus emblica Potentiates Indomethacin-Induced Gastric Ulcer Healing via e-NOS-Dependent Pathway.

Authors:  Ananya Chatterjee; Sirshendu Chatterjee; Angshuman Biswas; Sayanti Bhattacharya; Subrata Chattopadhyay; Sandip K Bandyopadhyay
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-26       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.